Evidence map›Paper›PMID 40629371›Full record

ArticleMalaria journal2025

Comparative susceptibility of wild and laboratory-reared Aedes and Anopheles larvae to ivermectin.

Cheick Oumar W Ouédraogo, Fabrice A Somé, André B Sagna, Emmanuel Sougué, Dieudonné D Soma, Mady Ndiaye, Fangala Hamidou Coulibaly, Sié H Pooda, Lamidi Zela, Christophe Roberge and 3 more

Abstract readComparative Study
In one paragraph

Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Cheick Oumar W OuédraogoInstitut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo-Dioulasso, Burkina Faso. cheickoumaroued92@yahoo.fr.
Fabrice A Somé *Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo-Dioulasso, Burkina Faso.
André B Sagna *MIVEGEC, Université de Montpellier, IRD, CNRS, Montpellier, France.
Emmanuel SouguéInstitut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo-Dioulasso, Burkina Faso.
Dieudonné D SomaInstitut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo-Dioulasso, Burkina Faso.
Mady NdiayeUniversité Cheikh Anta Diop de Dakar, Dakar, Sénégal.
Fangala Hamidou CoulibalyMIVEGEC, Université de Montpellier, IRD, CNRS, Montpellier, France.
Sié H PoodaUniversité Daniel-Ouezzin Coulibaly, Dédougou, Burkina Faso.
Lamidi ZelaUniversité Nazi Boni, Bobo-Dioulasso, Burkina Faso.
Christophe RobergeMedincell, Montpellier, France.
El Hadji A NiangUniversité Cheikh Anta Diop de Dakar, Dakar, Sénégal.
Karine MoulineMIVEGEC, Université de Montpellier, IRD, CNRS, Montpellier, France.
Roch K DabiréInstitut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo-Dioulasso, Burkina Faso.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdministering ivermectin to humans and livestock renders their blood toxic for mosquitoes like Anopheles and Aedes, offering a promising approach for controlling these vectors. However, the impact of such treatment on larval stages exposed to the drug through contaminated breeding sites is not fully understood. This study looked at how ivermectin affects the development of Aedes and Anopheles larvae.

methodsFour instars laboratory-reared (Anopheles gambiae Kisumu strain and Aedes aegypti Bora Bora strain) and wild-derived (Anopheles coluzzii VK5 and Ae. aegypti Bobo) larvae were exposed to ivermectin-medium containing the molecule at concentrations ranging from 0 to 100 ng/ml for 24 h, then transferred surviving larvae into ivermectin-free medium to monitor development until adult stage and female fecundity. Parameters measured were: larval survival, pupation dynamics, teneral emergence rates, and fecundity of the adult females in terms of numbers of eggs developed and laid. Two independent experiments were performed, each with four biological replicates. Data obtained for each life history parameter were compared between treatments to characterize ivermectin effects.

resultsData indicated that highest ivermectin concentrations (100, 75, and 50 ng/ml) reduced larval survival by over 50% within 24 to 48 h post-exposure, with varying effects across different strains. Wild-derived larvae showed lower susceptibility to ivermectin compared to laboratory larvae for both Anopheles and Aedes species. The concentrations leading to 50% larval mortality (4-day-LC50) were 3.65 and 1.86 ng/ml for Anopheles VK5 and Kisumu strains, and 15.60 and 2.56 ng/ml for Aedes Bobo and Bora Bora strains, respectively. Notably, while high concentrations severely impacted larval development, low concentration (1 ng/ml) appear to be a sublethal concentration and allowed for adult emergence. No significant effects on the number of laid eggs were observed across the different strains.

conclusionOverall, these data showed how development parameters of laboratory-raised and wild-derived Anopheles and Aedes larvae are affected differently by ivermectin, highlighting potential implications for vector control strategies and ecological concerns regarding non-target organisms and environment persistence. Further investigations are planned to understand existing mechanisms allowing wild-derived larvae to better survive than laboratory ones despite the presence of ivermectin in their breeding environment.

Indexed as

AedesAnophelesInsecticidesIvermectinMosquito VectorsAnimalsFemaleLarvaInsecticidesIvermectinAedesAnophelesIvermectinLarvaeSub-lethal concentrations, tolerance

Identifiers

PMID40629371
PMCPMC12239304

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.